We have been serving the pharmaceutical industry, and more generally the scientific research community, for more than 30 years.
Every member of our team is an experienced medical writer with a PhD, and all are native English or French speakers with bilingual proficiency in French and English. We design and write medical marketing documents intended for the scientific community, healthcare professionals or the general public, as well as all the regulatory and clinical documentation required at the various stages of drug development, regardless of the therapeutic area. We also provide an editorial assistance service to support you in the publication of your research: from the correction of your article to its submission, and the drafting of responses to reviewers.
We work accurately and efficiently to meet your deadlines, while our compliance with international standards (CONSORT, ICH, etc.), systematic proofreading between medical writers, and attention to detail guarantee that your documents will be of the highest quality. Our adaptability and responsiveness lead us to develop privileged and ongoing relationships with our clients.
Each project is unique, and our team at Santé Active Edition-Synergy Pharm are on hand to adapt and respond to your requirements. Do not hesitate to contact us to discuss your needs, we are looking forward to assisting you with your projects!
About 450,000 people are newly diagnosed with colorectal cancer each year in Europe, and around 140,000 people died from the disease across the EU-27 in 2016. In France, more than 43,000 new colorectal cancer cases and more than 17,000 deaths are estimated to occur each year. Screening enables colorectal cancer to be uncovered at an early stage, and the earlier it is detected, the greater the chances of recovery (the 5-year survival rate is 90% for the early stages).
Women and men aged 50 to 74 are invited every 2 years to have a rapid and effective test at home as part of the French colorectal cancer screening programme. Find out more about screening programmes in your country at https://digestivecancers.eu/colorectal-cancer/
Today is World Rare Disease Day and we would like to acknowledge the recent therapeutic advances that have brought hope to many patients and their families. Thank you to all who work in this field! Our team has a special interest in rare diseases; stemming both from the experience of two team members (Emma Pilling and Françoise Nourrit-Poirette) at Orphanet, and from our coverage of the North American Cystic Fibrosis Conference (NACFC). Marielle Romet, who is based in the United States, has attended the NACFC 4 years in a row and our team has coordinated the production of conference reports that were published live by the Pediatric Archives in partnership with the French Cystic Fibrosis Society, Elsevier and Vertex, and with the help of Profs. Isabelle Sermet, Isabelle Fajac, and Philippe Reix, and Drs. Valérie Urbach and Nadine Desmazes-Dufeu, and a group of French pulmonologists.
https://nacfc.elsevierresource.com/les-archives-des-congres-nacfc
Today is World Anosmia Awareness Day. Until recently, anosmia was a term understood mainly by patients, physicians and researchers; however, this term has now become familiar to the general public because anosmia is one of the common symptoms of Covid-19, particularly of the mild form of the disease (Lechien et al. 2021). Anosmia involves not only loss of the ability to detect odours, but also loss of the ability to sense food aromas and perceive flavours; the sense of taste only allowing the detection of sweet, savoury, sour, bitter and salty food. Loss of smell is very disturbing: it means loosing the everyday markers that are closely linked to odours and aromas. Although loss of smell is a short-term symptom for most Covid 19 patients, anosmia has been reported to persist for at least 6 months in patients with long Covid-19 (Lechien et al. 2021). Olfactory training is currently the only effective therapy for the treatment post-viral anosmia (French National Authority for Health, 2021), but oral corticosteroids may improve recovery of the sense of smell in Covid-19 patients (Le Bon et al. 2021; Vaira et al. 2020).